Arrowhead Files to Initiate Phase 1/2a Study for Complement Mediated Kidney Disease

 Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement mediated renal disease, such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-stage renal disease. Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation.

ARO-CFB is designed to reduce hepatic expression of complement factor B (CFB), which plays an important regulatory role in amplifying complement alternative pathway activation and has been identified as a promising therapeutic target.

https://www.biospace.com/article/releases/arrowhead-pharmaceuticals-files-for-regulatory-clearance-to-initiate-phase-1-2a-study-of-aro-cfb-for-complement-mediated-kidney-disease/